News in brief
Merck settles Zetia patent suit
Merck & Co has settled its patent litigation against generic drug firm Glenmark Pharmaceuticals over Merck’s cholesterol lowering
drug Zetia (ezetimibe). The case was set to go to trial on 12 May, after Glenmark sought US Food and Drug Administration approval
to market a generic version of ezetimibe, which is still under patent protection until April 2017. Under terms of the settlement,
Glenmark will be able to sell ezetimibe from December 2016.
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.